Literature DB >> 23892961

[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment].

Shoko Izaki1, Shinya Narukawa, Akihiro Kubota, Takao Mitsui, Hikoaki Fukaura, Kyoichi Nomura.   

Abstract

A 49-year-old female neuromyelitis optica spectrum disorder (NMOSD) patient with positive anti-aquaporin 4 (AQP4) antibody was treated with fingolimod (FTY720). Ten days later, she developed acute disturbance of consciousness, aphasia, right hemi-spatial neglect, and right hemiparesis. Brain MRI showed multiple white-matter lesions with slight Gadolinium enhancement. She was diagnosed of acute exacerbation of NMOSD. Thus, fingolimod may be associated with the development of a fulminant course in NMOSD patients with positive anti-AQP4 antibody.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23892961     DOI: 10.5692/clinicalneurol.53.513

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  10 in total

Review 1.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 2.  Immuno-pathogenesis of neuromyelitis optica and emerging therapies.

Authors:  Norio Chihara; Takashi Yamamura
Journal:  Semin Immunopathol       Date:  2022-05-30       Impact factor: 11.759

Review 3.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

Review 4.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 5.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

Review 6.  Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Authors:  Martin S Weber; Tobias Derfuss; Imke Metz; Wolfgang Brück
Journal:  Ther Adv Neurol Disord       Date:  2018-03-29       Impact factor: 6.570

Review 7.  MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.

Authors:  Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato
Journal:  Front Neurol       Date:  2018-04-04       Impact factor: 4.003

Review 8.  The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.

Authors:  Alexandra Lucaciu; Robert Brunkhorst; Josef M Pfeilschifter; Waltraud Pfeilschifter; Julien Subburayalu
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

Review 9.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 10.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Authors:  Giordani Rodrigues Dos Passos; Douglas Kazutoshi Sato; Jefferson Becker; Kazuo Fujihara
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.